%0 Journal Article
%T Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
%A Benjamin Solomon
%A Carol Colasacco
%A Christina B. Ventura
%A Dara L. Aisner
%A David J. Kwiatkowski
%A Eric H. Bernicker
%A Erik Thunnissen
%A Fred R. Hirsch
%A Jan A. Nowak
%A Keith Kerr
%A Lesley H. Souter
%A Lynette Sholl
%A Marc Ladanyi
%A Maria E. Arcila
%A Mary Beth Beasley
%A Ming S. Tsao
%A Murry W. Wynes
%A Neal I. Lindeman
%A Philip T. Cagle
%A Robyn Temple-Smolkin
%A Sanja Dacic
%A Yasushi Yatabe
%J The Journal of Molecular Diagnostics
%D 2018
%R 10.1016/j.jmoldx.2017.11.004
%X In 2013, an evidence-based guideline was published by the College of American Pathologists,
the International Association for the Study of Lung Cancer, and the Association for
Molecular Pathology to set standards for the molecular analysis of lung cancers to
guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation
of additional laboratory technologies, targetable genes, patient populations, and
tumor types for testing.
%U https://jmd.amjpathol.org/article/S1525-1578(17)30590-1/fulltext